Recently, a number of Southeast Asian countries, including the Philippines, Singapore, Vietnam, Myanmar, and Malaysia, have reported dengue fever outbreaks. The General Administration of Customs recently issued a new reminder, requiring customs to strengthen quarantine inspections for personnel from relevant countries (regions) to be vigilant against the spread of dengue fever. .

  Disease control experts said that dengue fever is an acute infectious disease caused by dengue virus. It is transmitted through the bite of Aedes mosquitoes. It mainly occurs in summer and autumn, and there is no specific drug.

Severe cases may progress to dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS).

  "Most of the attention on infectious diseases has now shifted to the new crown, and the monitoring of other diseases may be relaxed. At this time, we should be more vigilant." An infectious disease expert told Yicai.com reporter.

  Dengue fever is generally more common in regions with hot climates such as Southeast Asia and South America. There have also been many outbreaks in southern regions such as Guangdong, Yunnan, Fujian, and Hainan in my country.

Experts reminded that dengue fever is easy to be misdiagnosed and missed, and it is necessary to strengthen the training of medical staff, and to do a good job in mosquito control.

  In the past two years, due to the strengthening of border epidemic prevention due to the new crown epidemic, other imported infectious diseases have rarely been reported.

In 2020, the Shanghai Centers for Disease Control and Prevention reported 9 imported dengue fever cases, a decrease compared to the number of imported cases in previous years.

  Professor Lu Hongzhou, director of Shenzhen Third People's Hospital, told Yicai.com: "The incubation period of dengue fever is 3 to 15 days, most of which is 5 to 8 days, and the clinical manifestations are acute onset, ranging from mild fever to high fever. Accompanied by severe headache, muscle and joint pain and rash, flushing of face, neck and chest, severe cases may lead to death due to shock or other important organ damage."

  Lu Hongzhou believes that although there is a risk of imported dengue fever in my country, most of the 14-day entry quarantines currently implemented in my country have exceeded the incubation period for the onset of dengue virus.

  "The population base of dengue fever infection is relatively large, but more than 90% of the population have no disease or mild symptoms, so the overall mortality rate is not high. For patients who develop severe disease, the mortality rate can be as high as 50%, and preventing severe disease is the key. "One A dengue fever expert told the first financial reporter.

  Dengue virus serotypes are divided into 4 types (1, 2, 3, and 4), and the above-mentioned experts said that usually every year, there is a prevalent strain of dengue virus that dominates.

An estimated 390 million people worldwide are infected each year, 500,000 are hospitalized, and 20,000 die.

  According to the World Health Organization (WHO), the global incidence of dengue fever has increased significantly in recent decades, and about half of the world's population is at risk of dengue fever, but the WHO claims that early detection and appropriate medical care can reduce the mortality rate to 1 %the following.

  At present, there is no specific drug for dengue fever in the world, and symptomatic treatment is the mainstay, and there is no mature dengue fever vaccine marketed in China.

  Just on June 10, Takeda announced that its investigational dengue vaccine candidate, TAK-003, had achieved positive results in a pivotal Phase 3 clinical trial.

During a follow-up period of 54 months after vaccination, TAK-003 was 84% ​​effective in preventing hospitalization for dengue and 61% effective in preventing symptomatic dengue.

  TAK-003 is a quadrivalent vaccine based on attenuated dengue virus (serotype 2).

Trial results showed that TAK-003 was 84.1% effective in preventing dengue hospitalizations, 85.9% effective in seropositive individuals, and 79.3% effective in seronegative individuals.

Efficacy in preventing symptomatic dengue was 64.2% in seropositive individuals and 53.5% in seronegative individuals.

  In terms of safety, TAK-003 was well tolerated and no important safety risks were identified.

No evidence of disease enhancement was found in the 54-month follow-up analysis.

  In 2019, the U.S. FDA approved the listing of dengue fever Dengvaxia developed by Sanofi Pasteur, which is also the first dengue fever vaccine approved by the FDA. It is a chimera of dengue virus components and yellow fever virus 17D vaccine. The quadrivalent live attenuated vaccine, which consists of three injections with a 6-month interval between each injection, protects against dengue fever caused by all serotypes (types 1, 2, 3 and 4) of dengue virus, and clinical data show that, Among those aged 9 to 16, the vaccine was 76 percent effective.

However, this vaccine has been controversial because of the antibody-dependent enhancement effect (ADE).